However, pursuit of tissue-agnostic approvals in BRAFi was dissuaded by a phase II pilot study of vemurafenib in patients with BRAF V600E–mutant colorectal cancer that did not show meaningful clinical activity (202). This evidence concerns the gene BRAF and colorectal cancer.